Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J rivaroxaban (correction)

Executive Summary

Johnson & Johnson is developing the anticoagulant as an oral product only, not in multiple formulations. In a recent analyst update, the company suggested the product would offer an advantage in that the oral agent can be used both in the hospital and then later in the home (1"The Pink Sheet" June 11, 2007, p. 19)...

You may also be interested in...

J&J Growth Plan Calls For Four Virology Filings In As Many Years

Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts